Dual Renin-Angiotensin System Blockade in Heart Failure

Journal of the American College of Cardiology

Volumn 54, Issue 3, 2009, Pages 278-

  McMurray, John J V ^a   Granger, Christopher B ^a   Östergren, Jan ^a   Yusuf, Salim ^a   Pfeffer, Marc A ^a   Swedberg, Karl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADD ON THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LETTER; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 67649613555     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.02.073     Document Type: Letter

References (9)

1. Messerli F.H. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 53 (2009) 468-470
2. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
3. McMurray J.J., Östergren J., Swedberg K., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
4. McKelvie R.S., Rouleau J.L., White M., et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 24 (2003) 1727-1734
5. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6 (2004) 937-945
6. Desai A.S., Swedberg K., McMurray J.J., et al., CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 50 (2007) 1959-1966
7. McMurray J., and Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J 27 (2006) 1773-1777
8. Dickstein K., Cohen-Solal A., Filippatos G., et al., European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the ESC. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10 (2008) 933-989
9. Solomon S.D., Dobson J., Pocock S., et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007) 1482-1487